INSMED Inc (INSM) — SEC Filings

Latest SEC filings for INSMED Inc (INSM), explained in plain English.

Sentiment Overview: 1 bullish, 1 bearish, 45 neutral, 3 mixed

Recent Filings (50)

• INSMED Inc. Files 8-K with Regulatory Disclosures — 8-K · 2026-04-07T16:01:21-04:00 [neutral] Risk: low
  On April 7, 2026, INSMED Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements/Exhibits. The filing i
• DEFA14A Filing — DEFA14A · 2026-04-01T16:02:49-04:00 [neutral]
• Insmed Inc. Files 8-K on Dec 17, 2025 — 8-K · 2025-12-17T00:00:00.000Z [neutral] Risk: low
  Insmed Incorporated filed an 8-K on December 17, 2025, reporting on events including Regulation FD disclosures, other events, and financial statements. The comp
• 8-K Filing — 8-K · 2025-11-18T00:00:00.000Z [neutral]
• INSMED Inc. Files 8-K on Financials — 8-K · 2025-10-30T00:00:00.000Z [neutral] Risk: low
  On October 30, 2025, INSMED Incorporated filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well
• INSMED's Losses Widen Amid Soaring R&D, BRINSUPRI Launch Boosts Revenue — 10-Q · 2025-10-30T00:00:00.000Z [mixed] Risk: high
  INSMED Inc. reported a net loss of $370.0 million for the three months ended September 30, 2025, an increase from $220.5 million in the same period of 2024. For
• INSMED Inc. Files 8-K Report — 8-K · 2025-08-12T00:00:00.000Z [neutral] Risk: low
  On August 12, 2025, INSMED Incorporated filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regu
• INSMED Inc. Files 8-K on Operations and Financials — 8-K · 2025-08-07T00:00:00.000Z [neutral] Risk: low
  On August 7, 2025, INSMED Incorporated filed an 8-K report to disclose information regarding its results of operations and financial condition. The filing also
• INSMED's Q2 Loss Widens to $105.7M Despite 10.4% Revenue Jump — 10-Q · 2025-08-07T00:00:00.000Z [bearish] Risk: high
  INSMED Inc. reported a net loss of $105.7 million for the three months ended June 30, 2025, a significant increase from the $95.1 million net loss in the prior-
• INSMED Inc. Files 8-K with Financials and Exhibits — 8-K · 2025-06-13T00:00:00.000Z [neutral] Risk: low
  On June 11, 2025, INSMED Inc. filed an 8-K report to disclose information under Regulation FD and other events. The filing includes financial statements and exh
• INSMED Inc. Files 8-K Report — 8-K · 2025-06-10T00:00:00.000Z [neutral] Risk: low
  On June 10, 2025, INSMED Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, including financial statements and
• INSMED Inc. Files 8-K Report — 8-K · 2025-06-06T00:00:00.000Z [neutral] Risk: low
  On June 6, 2025, INSMED Inc. filed an 8-K report detailing "Other Events." The filing does not contain specific financial transactions or material business upda
• INSMED Inc. Reports Director, Officer, and Compensation Changes — 8-K · 2025-05-16T00:00:00.000Z [neutral] Risk: medium
  On May 15, 2025, INSMED Inc. filed an 8-K report detailing changes in its board of directors and executive officers, as well as updates to compensatory arrangem
• Insmed Inc. Files 8-K on Financials — 8-K · 2025-05-08T00:00:00.000Z [neutral] Risk: low
  Insmed Incorporated filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and ex
• Insmed Inc. Files Q1 2025 10-Q Report — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: medium
  Insmed Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025.
• Insmed Inc. Files 8-K/A Amendment — 8-K/A · 2025-04-24T00:00:00.000Z [neutral] Risk: low
  Insmed Incorporated filed an 8-K/A on April 24, 2025, to amend a previous filing. The amendment pertains to 'Other Events' and does not specify any new material
• INSMED Inc. Announces Board and CFO Changes — 8-K · 2025-04-17T00:00:00.000Z [neutral] Risk: medium
  On April 16, 2025, INSMED Incorporated announced changes in its executive leadership. The company elected two new directors, Dr. Ann M. D. Smith and Mr. David M
• DEF 14A Filing — DEF 14A · 2025-04-04T00:00:00.000Z [neutral]
• INSMED Inc. Files 8-K Report — 8-K · 2025-02-24T00:00:00.000Z [neutral] Risk: low
  On February 24, 2025, INSMED Incorporated filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
• 8-K Filing — 8-K · 2025-02-20T00:00:00.000Z [neutral]
• Insmed Inc. Files 2024 10-K Annual Report — 10-K · 2025-02-20T00:00:00.000Z [neutral] Risk: medium
  Insmed Inc. filed its 2024 10-K on February 20, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, headquarter
• INSMED Inc. Files 8-K Report — 8-K · 2025-02-06T00:00:00.000Z [neutral] Risk: low
  On February 6, 2025, INSMED Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation
• Insmed Acquires Calimmune for $125M+ — 8-K · 2025-01-10T00:00:00.000Z [bullish] Risk: medium
  Insmed Incorporated announced on January 10, 2025, that it has entered into a definitive agreement to acquire Calimmune, Inc. for an upfront payment of $125 mil
• Insmed Inc. Terminates Material Definitive Agreement — 8-K · 2024-11-19T00:00:00.000Z [neutral] Risk: medium
  Insmed Incorporated announced on November 18, 2024, the termination of a material definitive agreement. The company, incorporated in Virginia with its principal
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Insmed Inc. Enters Material Definitive Agreement — 8-K · 2024-10-31T00:00:00.000Z [neutral] Risk: medium
  Insmed Incorporated announced on October 31, 2024, that it has entered into a material definitive agreement. The company also reported its results of operations
• Insmed Inc. Files Q3 2024 10-Q Report — 10-Q · 2024-10-31T00:00:00.000Z [neutral] Risk: medium
  Insmed Inc. reported its third quarter 2024 results for the period ending September 30, 2024. The company's financial performance for this quarter is detailed i
• SC 13G Filing — SC 13G · 2024-09-03T00:00:00.000Z [neutral]
• INSMED Inc. Files 8-K for Undisclosed Event — 8-K · 2024-08-09T00:00:00.000Z [neutral] Risk: medium
  On August 9, 2024, INSMED Inc. filed an 8-K report to disclose an "Other Event." The filing does not contain specific details regarding the nature of this event
• Insmed Acquires Gene Therapy Company — 8-K · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Insmed Incorporated announced on August 8, 2024, that it has completed the acquisition of a gene therapy company for an undisclosed amount. This strategic move
• Insmed Inc. Files Q2 2024 10-Q Report — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Insmed Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial performance and operations. Key financial data and op
• Insmed Inc. Announces Definitive Acquisition Agreement — 8-K · 2024-07-03T00:00:00.000Z [neutral] Risk: medium
  Insmed Incorporated announced on July 3, 2024, that it has entered into a definitive agreement to acquire. This acquisition is expected to expand Insmed's pipel
• INSMED Inc. Files 8-K for Financial Statements — 8-K · 2024-06-27T00:00:00.000Z [neutral] Risk: low
  On June 27, 2024, INSMED Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other si
• INSMED Inc. Files 8-K Report — 8-K · 2024-06-13T00:00:00.000Z [neutral] Risk: low
  On June 12, 2024, INSMED Inc. filed an 8-K report to disclose other events. The filing does not contain specific financial figures or significant business updat
• INSMED Inc. Files 8-K Report — 8-K · 2024-06-04T00:00:00.000Z [neutral] Risk: low
  On June 4, 2024, INSMED Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific fina
• Insmed to Acquire Gene Therapy Co., Secures $1B Loan — 8-K · 2024-05-30T00:00:00.000Z [mixed] Risk: medium
  Insmed Incorporated announced on May 29, 2024, that it has entered into a definitive agreement to acquire a gene therapy company, pending customary closing cond
• INSMED Inc. Files 8-K Report — 8-K · 2024-05-28T00:00:00.000Z [neutral] Risk: low
  On May 28, 2024, INSMED Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Statements and E
• INSMED Inc. Reports Board and Executive Compensation Changes — 8-K · 2024-05-13T00:00:00.000Z [neutral] Risk: low
  On May 13, 2024, INSMED Incorporated filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the electio
• INSMED Inc. Files Current Report on Form 8-K — 8-K · 2024-05-09T00:00:00.000Z [neutral] Risk: low
  On May 9, 2024, INSMED Inc. filed an 8-K report detailing its financial results and other events. The company, incorporated in Virginia with its principal execu
• INSMED Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-09T00:00:00.000Z [neutral] Risk: medium
  INSMED Inc (INSM) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. INSMED Inc. reported financial results for the quarter ended March 31, 2024. The
• Insmed Inc. Files Definitive Proxy Statement — DEF 14A · 2024-04-01T00:00:00.000Z [neutral] Risk: medium
  INSMED Inc (INSM) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. Insmed Inc. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024. Th
• INSMED Inc. Files 8-K Report — 8-K · 2024-03-11T00:00:00.000Z [neutral] Risk: medium
  On March 8, 2024, INSMED Inc. filed an 8-K report to disclose "Other Events." The filing does not contain specific details about the nature of these events, dol
• INSMED Reports Material Agreements & Financial Condition — 8-K · 2024-02-22T00:00:00.000Z [mixed] Risk: medium
  INSMED Incorporated filed an 8-K on February 22, 2024, reporting on an entry into a material definitive agreement, the termination of a material definitive agre
• INSMED Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-22T00:00:00.000Z [neutral] Risk: medium
  INSMED Inc (INSM) filed a Annual Report (10-K) with the SEC on February 22, 2024. INSMED Inc. filed its 2023 Form 10-K on February 22, 2024. The filing covers t
• SC 13G/A Filing — SC 13G/A · 2024-02-16T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• BlackRock Amends INSMED Stake: Passive Investment Update — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating a change in its ownership of INSMED Inc. common stock as of December 31, 2023. This ame
• State Street Corp Updates Passive Stake in INSMED Inc. — SC 13G/A · 2024-01-22T00:00:00.000Z [neutral]
  State Street Corporation, a major financial institution, filed an updated SC 13G/A on January 22, 2024, disclosing its ownership of INSMED Inc. common stock as